DSIP (Delta Sleep-Inducing Peptide): What the Research Actually Shows
DSIP is a nine-amino-acid neuropeptide isolated from rabbit brain blood in 1974. In some animal studies it raises delta (slow-wave) EEG activity; in others it shows no effect, or the opposite. This research-use-only reference lays out both sides of that split literature, and the fact that its receptor and mechanism have never been identified.
Research-use-only disclaimer: DSIP supplied as a research chemical is intended strictly for in-vitro and laboratory research use and is not intended for human or veterinary use in that context. Every finding below is drawn from cell, animal, or human-imaging models and is described in hedged, mechanistic terms. Nothing here is medical advice.
TL;DR
DSIP is a nonapeptide (sequence WAGGDASGE) isolated from rabbit cerebral venous blood in 1974. In some animal studies it increases slow-wave sleep and total sleep time; in others it shows no effect, and one human study linked higher endogenous DSIP to less slow-wave and REM sleep. Its receptor and mechanism remain unidentified. It is a research compound, not a sleep drug.
Structure: nine residues, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE); isolated 1974.
Sleep, positive: some rat studies report more slow-wave sleep and longer total sleep.
Sleep, negative: other studies report no effect; one human study tied higher DSIP to less slow-wave and REM sleep.
Mechanism: no receptor, gene, or precursor identified. Unresolved.
Status: research-use-only; no established human effect.
What Is DSIP?
DSIP is a nonapeptide the Schoenenberger-Monnier group in Switzerland isolated in 1974 from the cerebral venous blood of rabbits held in an induced sleep state. Its amino-acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). The name describes what the discoverers observed, delta-wave sleep, not a proven mechanism. It is studied among cognitive, sleep, and mood research peptides.
What Does DSIP Do to Sleep in Animal Studies?
In the early work, infusing DSIP into recipient animals produced spindle and delta EEG patterns and reduced motor activity. A 1988 rat study reported that DSIP increased the share of slow-wave sleep and lengthened total sleep time, and linked it to sleep-related growth hormone release, per the PNAS report (1988). Those results are why DSIP entered the sleep-research literature.
Why Is the Evidence Mixed?
This is the part most product pages skip. Injecting DSIP into the dorsal raphe nucleus of rats produced no sleep effect in one study, and a human study of natural DSIP rhythms found that higher circulating levels tracked with less slow-wave and REM sleep, not more, as reported in the diurnal-rhythm study (1994). For a research audience, that inconsistency is the key result.
| Study / model | Reported result |
|---|---|
| Recipient rabbits, early work | Delta and spindle EEG; reduced motor activity |
| Rat, slow-wave sleep (1988) | Increased slow-wave sleep and total sleep time |
| Rat, dorsal-raphe injection | No sleep effect |
| Human, endogenous DSIP rhythm (1994) | Higher DSIP tracked with less slow-wave and REM sleep |
What Is DSIP's Mechanism?
Unknown. No DSIP receptor, gene, or precursor protein has been definitively identified, even decades after its discovery. That gap is unusual for a named neuropeptide and it is the main reason DSIP stays a research subject rather than a developed compound. Any page that states a confident mechanism is going beyond the evidence.
What Else Has DSIP Been Studied For?
Beyond sleep, DSIP has been examined for stress and neuroprotection endpoints. A 2021 rat study reported improved motor-function recovery after focal stroke, per the Molecules report (2021). These are single preclinical findings, not established effects, and none of them support human use.
How is research-grade DSIP characterized?
For reproducible sleep-EEG and neuro work, identity and purity are what matter. Research-grade DSIP is typically confirmed by reversed-phase HPLC for purity and mass spectrometry for identity, handled cold, and supplied for laboratory use only. At PrymaLab, research peptides are characterized with HPLC/MS verification and independent third-party testing. No specific lot data are asserted in this general reference.
Frequently Asked Questions
Does DSIP reliably improve sleep?
No. Animal and human findings are contradictory, and the mechanism is unknown. The evidence does not support a reliable sleep effect.
What is DSIP's amino-acid sequence?
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), a nine-residue peptide.
What is DSIP's mechanism of action?
Unknown. No receptor, gene, or precursor has been definitively identified, which is the defining open question in the DSIP literature.
Is DSIP approved for human use?
No. DSIP reference material is for laboratory research only. It is not a sleep aid or a drug.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977.
- Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci USA. 1988;85(10):3653–3657. PNAS
- Diurnal rhythm of plasma DSIP in humans and its relation to slow-wave and REM sleep. PubMed. 1994. PMID:8175965
- Delta sleep-inducing peptide and motor-function recovery after focal stroke in rats. Molecules. 2021;26(17):5173. MDPI
Final disclaimer: This article is an educational research reference. DSIP is sold and studied for laboratory research use only and is not approved by any regulatory authority for human or veterinary use. Statements have not been evaluated by the FDA. Nothing here should be interpreted as medical advice.
Mechanistic descriptions are observations from animal and human-imaging models that may not generalize; DSIP findings are notably inconsistent. Always verify the legal status of any research compound in your jurisdiction before purchase or use.
